Novartis names new Chief Digital Officer

pharmafile | August 29, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, appointment 

Novartis has announced that it has appointed a new Chief Digital Officer in the form of Bertrand Bodson, who will leave his current role as Chief Digital and Marketing Officer for Sainsbury’s Argos to join the company on 1 January, 2018, reporting directly to CEO Joe Jimenez.

Bodson’s remit will focus on the creation of a company-wide digital strategy which will seek to revolutionise the way Novartis applies and utilises data in drug development, business process automation, and interaction with patients, clinicians and shareholders. He will then lead the implementation of the strategy in close collaboration with Novartis’ Executive Committee and external partners and leadership teams across the company.

“Bertrand has a proven track record of creating and implementing successful digital strategies across global companies, and leading cultural change in order to make this happen at scale,” said Jimenez. “This is not just about digital helping the business. Bertrand will help us transform our business model using digital technologies.”

In his current role at Sainsbury’s Argos, Bodson has led the company in transforming itself from traditional catalogue retailer to become the third-largest online retailer in the UK. Prior to this role, Bodson has served in a senior capacity at Amazon in the US and Europe as well as EMI Music, and co-founded social network and content sharing site  

On his appointment, Mr Bodson remarked: “I am very excited to be joining Novartis to play a part in its efforts to reimagine medicine by leveraging digital on behalf of millions of patients and practitioners. While this will be one of the most important and disruptive challenges in the years to come, Novartis, as a global leader, is particularly well positioned to drive this, and have even greater and sustainable impact on healthcare worldwide.”

Related Content

FDA approves Novartis’ Fabhalta for PNH treatment

Novartis has announced that the US Food and Drug Administration has approved Fabhalta (iptacopan) as …

Ionis and Novartis partner for CVD treatment programme

Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Latest content